Tonix Pharmaceuticals (TNXP) investor relations material

Executive summary

• Net product revenue for Q1 2026 was $6.9 million, up from $2.4 million in Q1 2025, driven by the launch of TONMYA for fibromyalgia and continued sales of Zembrace SymTouch and Tosymra.

• First full quarter since TONMYA launch saw 2,145 prescribers, 3,588 patients initiating treatment, and approximately 5,400 prescriptions filled.

• Net loss increased to $40.2 million in Q1 2026 from $16.8 million in Q1 2025, reflecting higher R&D and SG&A expenses related to product launches and pipeline advancement.

• Cash and cash equivalents were $185.5 million as of March 31, 2026, with working capital of $177.5 million.

• Agreement with a leading GPO provides TONMYA access to 35 million U.S. commercial lives.

Financial highlights

• Product revenue rose 183% year-over-year to $6.9 million in Q1 2026.

• Cost of sales increased to $1.6 million from $0.9 million year-over-year.

• Research and development expenses surged to $18.2 million, mainly due to increased clinical, non-clinical, and manufacturing costs.

• Selling, general and administrative expenses rose to $28.6 million, driven by sales and marketing for TONMYA.

• Net cash used in operating activities was $42.3 million, up from $16.6 million in Q1 2025.

Outlook and guidance

• Cash resources and recent equity proceeds are expected to fund operations into early Q2 2027, but not for a full 12 months from the report date.

• Management highlights substantial doubt about the ability to continue as a going concern without additional funding.

• Additional capital will be required to support ongoing R&D and commercialization efforts.

• Adaptive Phase 2 field study for TNX-4800 (Lyme disease) planned for H1 2027, pending FDA agreement.

• Phase 2 study of TONMYA for MDD expected to begin mid-2026.